NAFENOPIN-INDUCED HEPATIC MICROBODY (PEROXISOME) PROLIFERATION AND CATALASE SYNTHESIS IN RATS AND MICE

Absence of Sex Difference in Response

JARNARDAN K. REDDY, DANIEL L. AZARNOFF, DONALD J. SVOBODA, and JADA D. PRASAD

From the Department of Pathology and Oncology and the Clinical Pharmacology and Toxicology Center, University of Kansas Medical Center, Kansas City, Kansas 66103

ABSTRACT
Nafenopin (2-methyl-2-[p-(1,2,3,4-tetrahydro-1-naphthyl)phenoxy]-propionic acid; Sul 13437), a potent hypolipidemic compound, was administered in varying concentrations in ground Purina Chow to male and female rats, wild type (Cs\(^+\) strain) and acatalasemic (Cs\(^-\) strain) mice to determine the hepatic microbody proliferative and catalase-inducing effects. In all groups of animals, administration of nafenopin at dietary levels of 0.125\% and 0.25\% produced a significant and sustained increase in the number of peroxisomes. The hepatic microbody proliferation in both male and female rats and wild type Cs\(^+\) strain mice treated with nafenopin was of the same magnitude and was associated with a two-fold increase in catalase activity and in the concentration of catalase protein. The increase in microbody population in acatalasemic mice, although not accompanied by increase in catalase activity, was associated with a twofold increase in the amount of catalase protein. The absence of sex difference in microbody proliferative response in nafenopin-treated rats and wild type mice is of particular significance, since ethyl-\(\alpha\)-p-chlorophenoxyisobutyrate (CPIB)-induced microbody proliferation and increase in catalase activity occurred only in males. Nafenopin can, therefore, be used as an inducer of microbody proliferation and of catalase synthesis in both sexes of rats and mice. The serum glycerol-glycerides were markedly lowered in all the animals given nafenopin, which paralleled the increase in liver catalase. All the above effects of nafenopin were fully reversed when the drug was withdrawn from the diet of male rats. During reversal, several microbody nucleoids were seen free in the hyaloplasm or in the dilated endoplasmic reticulum channels resulting from a rapid reduction in microbody matrix proteins after the withdrawal of nafenopin from the diet. Because of microbody proliferation and catalase induction with increasing number of hypolipidemic compounds, additional studies are necessary to determine the interrelationships of microbody proliferation, catalase induction, and hypolipidemia.

INTRODUCTION
Microbodies (peroxisomes), the cytoplasmic constituents described originally in kidney (1) and liver (2), have only recently been recognized as ubiquitous structures in animal (3-5) and plant...
cells (6). de Duve and associates (7–8) investigated the biochemical composition of microbodies of rat liver and showed that these structures possess catalase and several oxidative enzymes. It is evident from several studies that catalase is the only constant component of peroxisomes derived from different sources, whereas the hydrogen peroxide-generating oxidative enzymes that are associated with catalase differ in number and in specificity (9). On the basis of the cytochemical localization of catalase with the alkaline 3',3'-diaminobenzidine medium (10, 11), microbodies have been identified in tissues other than liver and kidney. Additional studies, however, are necessary to characterize the composition of these catalase-containing structures in other than liver and kidney either by biochemical or cytochemical procedures; and if the structures are found to possess at least one hydrogen peroxide-producing oxidase, they can then be unequivocally regarded as peroxisomes.

Although considerable progress has been made in the understanding of the functional role of peroxisomes in plant cells, the importance of these organelles in cellular metabolism in animal tissues remains to be elucidated. However, several studies suggest that microbodies may play a significant but as yet unexplained role in a variety of functions such as in gluconeogenesis, in cholesterol and steroid metabolism, in the detoxification of hydrogen peroxide, etc. (7, 12, 13). Studies with ethyl-α-p-chlorophenoxyisobutyrate (CPIB) have clearly established that this compound is valuable in investigating the biological behavior of microbodies under different experimental situations and also suggested a possible relationship between microbodies and lipid metabolism (13–18). CPIB is a potent hypolipidemic drug which lowers serum triglycerides and cholesterol in man (19) and in experimental animals (20). Administration of this drug to male rats results in a significant increase in the number of microbody profiles in liver cells (14–16). The CPIB-induced microbody proliferation in male rat liver was associated with a marked increase in catalase activity resulting from enhanced rate of synthesis of this enzyme (21). However, when CPIB was administrated to female rats in doses identical to those given to male rats for the same duration, there was no appreciable increase either in the number of microbody profiles or in the liver catalase activity. Similar sex differences in microbody proliferative and catalase response were observed in C3H mice and in wild type (Cs" strain) mice given CPIB, whereas no sex difference in microbody proliferative response was noted in acatalasemic (Cs" strain) mice (17).

Recently we have demonstrated that administration of nafenopin (2-methyl-2-[p-(1,2,3,4-tetrahydro-1-naphthyl)phenoxy]-propionic acid; Su-13437) to male rats, by gavage at 100 mg/kg body weight daily for 1–2 wk, results in a marked proliferation of hepatic microbody profiles with simultaneous increase in catalase activity (22). Nafenopin is structurally related to CPIB and on an equivalent weight basis is approximately five times as potent as CPIB in producing hypolipidemia and hepatomegaly (23, 24). In the present investigation varying concentrations of nafenopin were administered in ground Purina Chow ad lib to both male and female rats, wild type (Cs" strain) mice and acatalasemic (Cs" strain) mice, in order to determine the dose-response relationship and to ascertain the species and sex differences, if any, in microbody proliferative response and inducibility of liver catalase. The results indicate an absence of sex difference in microbody proliferative response in nafenopin-treated rats and wild mice, whereas CPIB-induced microbody proliferation occurred only in males (16). Accordingly, nafenopin can be used as an inducer of microbody proliferation and of catalase enzyme synthesis in both sexes of rats and mice. These studies also emphasize the significance of hypolipidemic drugs as effective tools for investigating the interrelationship of microbodies with lipid metabolism.

MATERIALS AND METHODS

Animals and Treatment

The inbred rats used in these experiments were of the F-344 strain (Simonson Laboratories Inc., Gilroy, Calif.) weighing between 125 and 175 g, which were maintained in individual cages. The wild type (Cs" strain) mice and the acatalasemic (Cs" strain) mice used in these experiments were 2–6 mo old and weighed between 20 and 30 g. Nafenopin (CIBA Pharmaceuticals, Summit, N. J.) was added to the ground Purina Chow in concentrations of 0.0125%, 0.05%, 0.125%, and 0.25% and was thoroughly mixed. Preliminary studies in rats indicated that nafenopin at 0.125% and 0.25% dietary levels was very effective in inducing microbody proliferation. Accordingly, studies in wild type and acatalasemic mice were conducted with these two dose levels. At the end of 1, 2, 3, 4, 6, and 8 wk, liver tissue for morphological studies was obtained from two to three animals from each of the treated groups after laparot-
omy or sacrifice. The reversal of nafenopin-induced microbody proliferation was investigated in male rats. After receiving 0.25% nafenopin for 6 wk, animals were killed on days 1, 3, 5, 7, 10, and 14 after withdrawal of the drug for ultrastructural studies and catalase assay.

**Morphology**

For light microscope examination, samples of liver were fixed in neutral buffered formaldehyde and embedded in paraffin. 3-5 µm sections were stained with hematoxylin and eosin. For electron microscope studies, tissues were fixed for 1-2 h at 4°C in 25% osmium tetroxide buffered with S-collidine to pH 7.4, and processed as described previously (15). For cytochemical localization of catalase, selected samples of liver from treated and untreated animals were fixed in 2.5% glutaraldehyde buffered with 0.1 M sodium cacodylate, pH 7.4, for 4 h at 4°C. After fixation, the tissues were rinsed overnight in 0.1 M cacodylate buffer containing 0.2 M sucrose. Then the tissues were finely chopped with a Sorvall “chopper” (Ivan Sorvall, Inc., Newtown, Conn.) and incubated at 37°C for 30-45 min in the 3',3'-diaminobenzidine oxidation medium of Novikoff and Goldfischer (10) and processed for electron microscope examination.

**Assay of Liver Catalase Activity**

After determining that nafenopin at 0.125% and 0.25% caused maximal proliferation of microbodies, in both male and female animals, we limited the biochemical studies of catalase to these two dietary levels. The animals were killed by light ether anaesthesia and the livers were removed and weighed. 5% liver homogenates were prepared to which sodium deoxycholate (DOC) was added to give a final DOC concentration of 0.5% (25). This mixture was incubated at room temperature for 30 min and then centrifuged in a Spinco model L ultracentrifuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) using a 50 rotor at 35,000 rpm for 85 min. After centrifugation the lipid-containing layer at the top was carefully removed and the supernate was assayed for catalase activity at 25°C by the spectrophotometric method described by Lück (26). Total proteins were determined by the method of Lowry et al. (27).

**Quantitation of Liver Catalase Protein**

**IN RATS:** Content of catalase protein in normal and nafenopin-treated male and female rats was determined by immunotitration method described by Ganschow and Schimke (25).

**IN WILD AND ACATALASEMIC MICE:** In order to determine the content of liver catalase protein among control and nafenopin-treated wild type (Ca<sup>+</sup> strain) and acatalasemic (Ca<sup>−</sup> strain) mice, immunoprecipitation of protein reactive with antibody specific for catalase was undertaken. The anticalatalase serum was obtained by injecting rabbits with catalase purified from the livers of Ca<sup>+</sup> strain mice. By the Ouchterlony double diffusion method, this antisera gave single precipitin lines with wild and acatalasemic liver extracts.

The content of liver catalase protein in control and nafenopin-treated wild type male and female mice was determined by the immunotitration method referred to above (25). Quantitation of liver catalase protein in acatalasemic mice by the immunotitration method could not be performed, because of low levels of catalase activity (17, 28) and also because of rapid inactivation of catalase when incubated at 37°C (29). In order to compare the amount of catalase protein in livers of acatalasemic and wild type mice, equal amounts of liver extracts from normal and nafenopin-treated animals were incubated with quantities of antisera that were found to neutralize the catalase protein in normal and nafenopin-treated wild type mice. The immunoprecipitates were centrifuged and washed twice with cold 0.15 M sodium chloride. The washed precipitates were dissolved in 0.1 M sodium hydroxide and the absorbance at 280 nm was measured.

**Serum Cholesterol and Triglycerides**

All animals were lightly anesthetized with ether. Blood was collected from the inferior vena cava from nonfasted animals between 9 and 10 a.m. Serum total cholesterol and/or glyceride glycerol were determined after quantitative separation on silicic acid from phospholipids by the micromethod described by Azarnoff (30).

**RESULTS**

**Studies in Rats**

**MICROBODY PROLIFERATION:** With 0.0125% of nafenopin for 2 wk, the liver weights were only slightly increased. Nafenopin given at 0.125% and 0.25% produced a marked increase in liver weights in both male and female rats (Table I). Light microscope examination of these livers revealed greatly enlarged hepatocytes containing abundant acidophilic, finely granular cytoplasm. During the initial states of nafenopin treatment, numerous mitoses of liver cells were encountered. Autoradiographic studies, after [3H]<sub>2</sub>thymidine pulse, during the first week of nafenopin administration showed numerous labeled hepatocyte nuclei in male and female rats.1

---

1 Reddy, J., and Prasad, J. Unpublished observations.
TABLE I
Effect of Feeding F-344 Rats with Nafenopin on Liver Weight, Liver Catalase Activity, Serum Cholesterol, and Serum Glyceride-Glycerol Concentrations

| Group* | No. of animals | Liver weight † | Liver catalase activity ‡ | Serum cholesterol ‡ | Serum glyceride-glycerol ‡ |
|--------|----------------|----------------|--------------------------|---------------------|-----------------------------|
| Male rats |                 |                |                          |                     |                             |
| Controls | 6              | 3.75 ± 0.42    | 38.0 ± 3.9               | 82 ± 5              | 10.6 ± 2.8                   |
| Nafenopin (0.125%) | 5              | 8.09 ± 0.52    | 74.9 ± 5.1               | 86 ± 9              | 2.9 ± 0.6                    |
| Nafenopin (0.25%) | 6              | 8.34 ± 0.48    | 86.1 ± 4.3               | 79 ± 8              | 1.6 ± 0.2                    |
| Female rats |                 |                |                          |                     |                             |
| Controls | 6              | 3.21 ± 0.36    | 31.2 ± 3.7               | 76 ± 4              | 9.7 ± 2.4                    |
| Nafenopin (0.125%) | 4              | 7.95 ± 0.18    | 71.4 ± 4.2               | 66 ± 4              | 2.5 ± 0.3                    |
| Nafenopin (0.25%) | 5              | 8.10 ± 0.04    | 82.7 ± 1.25              | 74 ± 6              | 2.3 ± 0.5                    |

* Nafenopin was administered in ground Purina Chow for 4 wk.
† Mean ± standard error.

Increase in the number of microbody profiles was evident in both sexes of rats given various dietary concentrations of nafenopin. 1-µm sections of Epon-embedded material clearly suggested that the increase in microbodies is generalized in the cytoplasm of liver cells throughout the entire liver lobule. With 0.0125% nafenopin, the microbody increase was slight when compared to the degree of proliferation encountered with higher dose levels. The microbody profiles were most numerous in liver cells of male and female rats (Fig. 1) given 0.125% nafenopin. With 0.25% nafenopin, there was no additional increase in number of microbody profiles. The microbody proliferation in both sexes of rats treated with 0.125% and 0.25% nafenopin was found to be of the same magnitude. Prolonged treatment with nafenopin resulted in the persistence of an increased number of peroxisomal profiles in male and female rats. Conspicuous variations in size and shape of microbody profiles were apparent. Nucleoids were observed in many microbody profiles of different sizes and configurations. Abnormalities in size and shape of peroxisomal profiles were striking in animals given 0.0125% nafenopin. Several of these microbody profiles contained striations in the matrix (Fig. 2), similar to those seen in CPIB-treated animals (14). A number of microbody profiles in liver cells of animals on prolonged nafenopin treatment possessed a somewhat flocculent matrix. However, all these organelles stained positively for catalase when incubated in the alkaline 3',3'-diaminobenzidine medium. This reaction was inhibited when tissues were incubated in the presence of aminotriazole.

In addition to showing microbody proliferation, the liver cells of nafenopin-treated animals revealed marked proliferation of smooth endoplasmic reticulum. Isolated channels of rough endoplasmic reticulum were also frequently encountered. Mitochondria appeared normal in size, shape, and number. They did not show any inclusions or other obvious structural abnormality (Fig. 1). There was no increase in the number of lysosomes or lipid droplets in nafenopin-treated livers. Many hepatocyte nucleoli were hypertrophied.

MICROBODY REVERSAL: Rats treated with nafenopin for 6 wk showed increase in the number of microbody profiles to the same extent as evidenced at 4 and 8 wk. Gradual depletion in the number of microbody profiles was noted during the first 7 days after withdrawal of nafenopin. By 14 days after the drug was discontinued, the number of microbody profiles returned to normal. The reduction in microbody profiles was imperceptible in that there was no appreciable evidence of cellular autophagy. Detailed examination of livers during the first week of nafenopin withdrawal revealed certain interesting morphological features (Figs. 3–7). Marked decrease in electron...
Figure 1  Female rat liver. Nafenopin 0.125% in the diet for 4 wk. The microbody proliferation in female rat liver cells was comparable to that observed in male rats. Significant variation in size and shape of microbody profiles (mb) is evident. Nucleoids (n). X 14,500.
opacity of the matrix was noted in some microbody profiles. Several dilated endoplasmic reticulum channels contained crystalline microbody nucleoids or cores (Figs. 3 and 4) without the background matrix proteins, suggesting a gradual depletion of matrix proteins presumably due to cessation of synthesis after nafenopin withdrawal. Extrusion of nucleoids into hyaloplasm was also seen. At 7 days after withdrawal of nafenopin, occasional examples of nucleoids lying free in the hyaloplasm were also encountered (Figs. 6 and 7).

**Liver Catalase:** The results in Table I indicate that the activity of catalase in the liver in both male and female rats increased about two-fold on administration of 0.125% or 0.25% nafenopin. When liver catalase activities were determined in male rats treated with 0.25% nafenopin for 2–14 days, it was found that the activity of catalase increases progressively, reaching the steady state level in 8–12 days. Nafenopin appeared as effective as CPIB in increasing the liver catalase activity. It is of interest to note that the induced steady state of catalase activity with these two drugs is nearly the same, i.e. approximately twice that of the normal steady state.

The results of immunotitration of liver catalase in male and female rats treated with 0.25% nafenopin for 4 wk are shown in Fig. 8. The amount of anticatalase serum needed to precipitate completely the catalase activity from 1 ml of 5% liver extract of either male or female rat treated with nafenopin was two times greater than that required for extracts from livers of untreated controls. These results indicate that the amount of catalase protein in liver extracts of male and female rats given nafenopin was the same and that nafenopin causes a twofold increase in the amount of liver catalase protein when compared to controls.

By 10 days after withdrawal of nafenopin from the diet, the catalase activity in liver reverted to normal values which paralleled the reduction in the number of hepatic microbody profiles.

**Serum Cholesterol and Serum Glyceride Levels:** Administration of nafenopin at 0.125% and 0.25% to both male and female rats produced no significant cholesterol-lowering effect at 4 wk. In direct contrast, however, a profound reduction in serum glyceride levels was obtained in both males and females (Table I). Within 7–10 days after withdrawal of the drug the serum glyceride levels returned to normal, which paralleled the reduction in catalase activity and the number of microbody profiles.

**Studies in Mice**

**Microbody Proliferation:** Nafenopin was given to both sexes of wild type (Cs strain) and acatalasemic (Cs b strain) mice at dietary levels of 0.125% and 0.25%. The gain in body weight was not affected at 0.125% dose level, whereas at 0.25% level there was some reduction in weight gain. However, at both these levels, nafenopin produced a marked increase in the weight of the liver in both males and females. In wild type mice fed 0.125% nafenopin for 4–8 wk the liver weight was approximately 25% of the body weight (Table II). Similar increases in liver weight were also seen in both sexes of acatalasemic mice treated with nafenopin. Examination of these livers with the light microscope showed large polygonal liver cells with abundant cytoplasm. Several mitotic figures were seen in the livers of animals killed during the first 10 days of nafenopin administration, suggesting that nafenopin-induced increases in liver weight are due in part to cell multiplication and cellular hypertrophy.

The microbody proliferation was most pronounced in the livers of both sexes of wild type and acatalasemic mice given 0.125% nafenopin (Fig. 9). Further increase in the number of microbody profiles was not seen with the higher dose level. In previous studies, we did not observe any increase in the number of microbody profiles in the female wild type (Cs strain) mice treated with CPIB, although CPIB produced a marked increase in hepatic microbody population in both sexes of acatalasemic (Cs b strain) mice (17). The absence of sex difference in microbody proliferation in response to nafenopin, in rats and mice, is of particular interest.

The microbody profiles were numerous and showed a great deal of variation in size and shape. Continuities between adjacent microbody profiles and between microbody profiles and smooth endoplasmic reticulum channels were noted frequently (Figs. 10 and 11). Structural changes in mitochondria were not seen, and because of marked increase in microbody profiles, the mitochondria appeared sparse. Proliferation of smooth endoplasmic reticulum was observed in the liver cells of all animals treated with nafenopin.
Liver Catalase: The results of the determination of catalase activity in livers of acatalasemic and wild type mice are shown in Table II. After nafenopin treatment, the catalase activity in male and female wild type mice (Cs<sup>a</sup> strain) was significantly increased. The amount of catalase protein in liver of untreated and treated Cs<sup>a</sup> mice was determined by the immunotitration method.

For complete precipitation of the catalase activity from 1 ml of 2.5% liver extract of Cs<sup>a</sup> mice treated with nafenopin for 8 wk, approximately 0.64 ml of anticatalase serum was required, whereas only 0.31 ml antiserum was required to precipitate the catalase activity from 1 ml of 2.5% liver extracts from untreated wild mice. From these findings it can be reasonably assumed that a twofold increase in concentration of catalase protein occurs in livers of Cs<sup>a</sup> mice treated with nafenopin.

Acatalasemic (Cs<sup>b</sup>) mice treated with nafenopin showed only a minimal increase in liver catalase activity (Table II), although the microbody population in liver cells was comparable to that encountered in male and female wild type (Cs<sup>a</sup>) mice. Studies of Aebi et al. (29) demonstrated that acatalasemic mutant mice have an unstable catalase that is unusually heat labile. The catalase in the present studies was assayed on liver extracts treated earlier with DOC and kept at room temperature for 30 min (see Materials and Methods). Accordingly, the low levels of catalase in nafenopin-treated Cs<sup>b</sup> mice may be, in part, due to inactivation at room temperature.

To determine the quantity of catalase protein in acatalasemic mice, 0.31 ml and 0.64 ml of anticatalase serum were added, respectively, to 1 ml samples of 2.5% liver extracts from control and nafenopin-treated animals. The amount of anticatalase serum used was the same that was found to precipitate all the catalase activity in wild type mice by the immunotitration method (see above). The amount of protein precipitated from nafenopin-treated, acatalasemic mouse liver extracts was approximately twice that precipitated from control mouse liver extracts. Furthermore, the amounts of protein precipitated...
TABLE II

Effect of Feeding Wild Type (C3a Strain) Mice and Acatalasemic (Csb Strain) Mice with Nafenopin on Liver Weight, Liver Catalase Activity, and Serum Glyceride-Glycerol Levels.

| Group*              | No. of animals | Liver weight g/100 g body weight | Liver catalase activity U/mg protein | Serum glyceride-glycerol mg/100 ml |
|---------------------|----------------|----------------------------------|-------------------------------------|-----------------------------------|
| Wild type (C3a) mice |                |                                  |                                     |                                   |
| Males control       | 6              | 5.3 ± 0.30                       | 38.8 ± 3.1                          | 11.6 ± 1.8                        |
| Males nafenopin     | 4              | 24.6 ± 2.80                      | 76.3 ± 5.6                          | 4.2 ± 0.4                         |
| Females control     | 5              | 4.9 ± 0.26                       | 37.2 ± 4.3                          | 10.5 ± 1.3                        |
| Females nafenopin   | 4              | 26.5 ± 1.70                      | 71. ± 5.4                           | 4.1 ± 0.6                         |
| Acatalasemic (Csb) mice |            |                                  |                                     |                                   |
| Males control       | 6              | 5.6 ± 0.25                       | 10.5 ± 3.6                          | 5.7 ± 1.7                         |
| Males nafenopin     | 4              | 18.7 ± 1.90                      | 15.2 ± 2.7                          | 1.9 ± 0.6                         |
| Females control     | 4              | 5.0 ± 0.40                       | 11.3 ± 3.2                          | 5.3 ± 2.2                         |
| Females nafenopin   | 4              | 19.8 ± 2.75                      | 13.4 ± 2.8                          | 2.1 ± 0.8                         |

* Nafenopin (0.125%) was given in ground Purina Chow for 8 wk.

Table II indicates the liver weight and catalase activity from the liver extracts of acatalasemic and wild type mice were also comparable. From these results it can be assumed that nafenopin causes approximately a twofold increase in the quantity of liver catalase protein in acatalasemic mice.

**Serum Glyceride Levels:** The results listed in Table II indicate that serum glyceride-glycerol levels are considerably lower in the acatalasemic mice than in the wild type mice. These findings in untreated controls are in agreement with the observations of Goldfischer et al. (31). After treatment with 0.125% nafenopin for 8 wk, the serum glyceride levels in both sexes of acatalasemic and wild type mice were markedly lowered (Table II). Serum cholesterol levels of these mice were not determined in this study.

**DISCUSSION**

Unlike other cellular constituents, microbodies (peroxisomes) in hepatic parenchymal cells are infrequently altered in number or morphology by experimental manipulations. However, markedly reduced activities of catalase and/or other peroxisomal enzymes in the liver have been observed in certain conditions, particularly in tumor-bearing animals (32). Quantitative studies to date indicate that CPIB and acetylsalicylic acid are the only known compounds that are capable of inducing significant increase in the number of microbody profiles in male rat liver cells and that the microbody proliferative response induced by CPIB is more pronounced in comparison to that induced by acetylsalicylic acid (14, 15, 33). Concomitant with the increase in microbody profiles, the liver catalase activity is increased twofold after CPIB treatment due to enhanced synthesis of this enzyme (21). Additional studies by Svoboda, Azarnoff, and Reddy (16) demonstrated that in rats, CPIB-induced microbody proliferation and rise in catalase levels are dependent, to a significant degree, upon male sex hormones.

In the present study, microbody proliferation in both male and female rats treated with higher doses of nafenopin (0.125% and 0.25%) was very pronounced. Marked increase in the number of microbody profiles was also observed in both sexes of wild type and acatalasemic mice given nafenopin. The microbody proliferation induced with 0.125% nafenopin in these animals was of the same degree as that induced by 0.25% CPIB (14, 15, 17). In addition, these studies have also shown a twofold increase in the hepatic catalase activity and in the amount of catalase protein in both sexes of rats and wild type mice treated with nafenopin. Although the increase in catalase activity was not significant in acatalasemic mice given nafenopin, the amount of liver catalase protein in these animals was approximately equal to that found in nafenopin-treated wild type mice.

Nafenopin, like CPIB, is a phenolic ether which produces in rats a significant reduction in serum triglycerides, but does not significantly reduce the serum cholesterol (24). Serum glycerol-glycerides were significantly lowered in rats and mice given nafenopin in the present investigation. The studies of Best and Duncan (24) indicate that somewhat
Figure 9  Female wild type mouse (Cs° strain). Nafenopin 0.125% for 4 wk. Marked increase in number of microbody profiles (mb) is seen. The microbody proliferation in male Cs° mice treated with nafenopin was of similar magnitude. × 19,000.
less than one-fifth as much nafenopin as CPIB is required to produce similar degrees of hepatomegaly and reduction in serum triglycerides in rats. With 0.125% and 0.25% nafenopin, the liver weights of rats in the present study were significantly higher than in rats given 0.25% CPIB (15). The hepatomegaly was most striking in wild type and acatalasemic mice treated with 0.125% nafenopin. In these animals, approximately 3 wk of nafenopin administration resulted in massive enlargement of livers, which accounted for one-fifth to one-fourth of the total body weight. Prolonged treatment for 8 wk did not show significant additional increase in liver weight. Although microbody proliferation undoubtedly contributed to hepatocellular hypertrophy in these animals, preliminary studies using [3H]thymidine autoradiography suggest that nafenopin induces hepatocellular proliferation during the initial stages, resulting in an increase in liver cell population. After the regenerative phase, the liver cells appear to undergo marked hypertrophy (34).

Previous studies from this laboratory demonstrated a distinct sex difference in microbody proliferative response and in liver catalase inducibility in rats, C3H mice, and in wild type (C57B) mice, after CPIB administration (15-17). In females, CPIB failed to induce microbody proliferation and increase in liver catalase activity. However, when castrated female rats were given testosterone propionate together with CPIB, there was a marked increase in the number of microbody profiles and in hepatic catalase activity (16). In the present study, however, in contrast to the situation with CPIB, nafenopin induced more or less similar degrees of microbody proliferation and catalase induction in both sexes of rats and wild type mice. Sex differences in the metabolism of drugs and in the inducibility of microsomal enzyme systems in rodent liver have been established in several instances (35, 36). The reasons for this differential ability of CPIB and nafenopin in inducing microbody proliferation and catalase synthesis in male and female animals can not be stated with certainty from these experiments. Although CPIB and nafenopin are struc-
turally similar hypolipidemic phenolic ethers, there may exist differences in their metabolism. It is possible that the microbody proliferative effect of CPIB is dependent upon excessive ana-
abolic activity, whereas nafenopin may be less dependent, or may possess androgenic activity. The absence of sex difference in response to nafeno-
pin-induced microbody proliferation and catalase synthesis may be due to the fact that this com-
pound is about five times more potent than clofi-
brate (CPIB) in producing hypotriglyceridemia (23, 24). Further clarification would probably be ac-

tained by evaluation of the close in relation to
reduction of plasma cholesterol and triglyceride
levels. It is not known if CPIB, in concentrations
greater than 0.25% in diet, would cause micro-
body proliferation in female rats and mice. This
may not occur in view of the finding that the
effect on lipids actually decreases when CPIB is
given in doses greater than 0.25%. Despite the
uncertainty in understanding the basic differ-
ence(s) in the action of these drugs in inducing
microbody proliferation in one or both sexes of
rats and mice, the present study clearly identifies
nafenopin as an effective inducer of microbody
proliferation and of catalase synthesis in both
sexes.

In contrast to a sex difference in response to
CPIB in rats and mice cited above, no such
difference was observed in acatalasemic “mu-
tant” mice (17). Both male and female acatala-
semic mice given CPIB showed profound increase
in number of hepatic microbody profiles. This
may be in part due to the genetic makeup of this
mutant mouse strain, because, within a given
species, genetic variation may be important in
determining the occurrence or magnitude of en-
zyme induction (35). Microbody proliferative
response in both sexes of acatalasemic mice after
nafenopin was identical to that obtained after
the administration of CPIB.

The increase in catalase activity and in the
number of catalase protein in liver of rats treated
either with nafenopin or with CPIB was twice
that of controls. It is of interest to note that the
induced steady state of liver catalase in rats is
never more than twofold. Furthermore, even in
animals given diets containing both nafenopin
and CPIB, the concentration of liver catalase did
not exceed this level. The amount of liver catalase
protein in these animals, therefore, does not
correspond with the severalfold increase in the
number of microbody profiles. Although, cyto-
chemically, catalase was demonstrable in all the
microbody profiles, the possibility that these
structures proliferating under the influence of
nafenopin or CPIB (37) possess a low concen-
tration of catalase cannot be excluded. This is not
surprising in view of our earlier observation that
CPIB induces hepatic microbody proliferation in
animals treated with allylisopropylacetamide, a
drug which completely inhibits the catalase
synthesis (18).

The relationship between the increase in the
number of hepatic microbody profiles and decrease
in serum cholesterol and/or triglycerides resulting
from the administration of CPIB and nafenopin,
is not clear. Despite numerous investigations, the
mechanism by which CPIB elicits the hypolipi-
demic and microbody proliferative responses
cannot be stated with certainty. Since nafenopin
is a relatively new compound in the expanding
field of hypolipidemic agents, studies dealing with
the mechanism of its action are lacking, because
it was withdrawn from clinical studies after it
was found to produce liver tumors in mice.2 Re-
duction in serum glycerides and induction of
hepatic microbody proliferation and of catalase
appear to be the common properties of these two
drugs. Because of the significant increase in micro-
body population and in catalase activity resulting
from CPIB, Svoboda and Azarnoff (14) invoked
a possible relationship between CPIB-induced
microbody proliferation and hypolipidemia. A
similar relationship between microbodies and
lipid metabolism was suggested earlier by Novi-

koff and Shin (12) on the basis of the observation
of Hochstein and Ernster (38) that the rat liver
micr...
demonstration of an abnormality of hepatic lipogenesis in this mutant strain (41).

In view of the reports dealing with the effect of catalase on cholesterol, it appeared reasonable to assume that the hypolipidemic effect of CPIB was the result of endogenous elevation of liver catalase produced by microbody proliferation (14). However, accumulated evidence indicates that the hypolipidemic and microbody proliferative effects of CPIB are possibly independent (15, 16, 18, and 42). In the present study, the demonstration of microbody proliferation and catalase induction after administration of nafenopin, a potent hypolipidemic drug, again raises the question of possible relationship between microbody proliferation and hypolipidemia. In this regard, it is also pertinent to state that methyl clofenapate (43), a hypolipidemic analogue of CPIB, also causes a very significant hepatic microbody proliferation. On an equivalent weight basis, methyl clofenapate appears to be 5-10 times as potent as nafenopin or CPIB in inducing microbody proliferation. These drugs promise to be of considerable value for studying the functional significance of microbody proliferation in the production of hypcholesterolemia and hypotriglyceridemia. Furthermore, acetylsalicylic acid which induces microbody proliferation is also known to reduce serum cholesterol levels (42). It is, therefore, necessary to investigate the structural analogues of CPIB in an attempt to determine the interrelationships of chemical configuration of these drugs, microbody proliferation, catalase induction, and hypolipidemia.

Although the role of drug-induced hepatic microbody proliferation is not understood, the widespread occurrence of microbodies in several cell types of vertebrates has given rise to additional speculation regarding their functional significance and has been the subject of discussion in a recent symposium. In view of their widespread distribution among tissues and species, the possibility that microbodies may perform different functions in different cell types cannot be excluded, although their role in lipid metabolism and in detoxification of H₂O₂ may be considered universal (13).

The observations on microbody profiles during recovery after withdrawal of nafenopin were similar to those seen in rats after CPIB (44). Dissolution of the microbody matrix, appearance of nucleoid cores in dilated endoplasmic reticulum membranes or occasionally in the hyaloplasm, are the significant findings. Incorporation of microbody profiles into lysosomes or into autophagocytic vacuoles was not detected. It appears that cessation of enhanced synthesis of peroxisomal proteins after discontinuation of nafenopin is responsible for the reduction in the peroxisomal protein pool. The reduction in number of microbody profiles appears to be due to progressively diminishing quantities of peroxisomal matrix proteins in endoplasmic reticulum channels.

Nafenopin was supplied by Dr. William E. Wagner, CIBA Pharmaceuticals, Summit, N. J. Technical assistance was given by Ms. Lynne Schmutz, Ms. Faye Brady, Ms. Dianne Knox, Ms. Mary Ann Wickham, and Mr. Charles Sittler. Mrs. Ella M. Olson provided the editorial assistance.

This work was supported by United States Public Health Service grants GM-13956 and CA-5680.

Received for publication 16 August 1973, and in revised form 3 December 1973.

REFERENCES

1. RHODIN, J. 1954. Correlation of ultrastructural organization and function is normal and experimentally changed proximal convoluted tubule cells of the mouse kidney. Doctorate Thesis. Karolinska Institutet, Stockholm.

2. ROULLER, C., and W. BERNHARD. 1956. "Microbodies" and the problem of mitochondrial regeneration in liver cells. J. Biophys. Biochem. Cytol. 2(Suppl.) :355.

3. HRUBAN, Z., and M. RECHCIGL, JR. 1969. Microbodies and related particles. Morphology, biochemistry and physiology. Int. Rev. Cytol. 1(Suppl) :20.

4. HRUBAN, Z., E. VIGIL, A. SLEESERS, and E. HOPKINS. 1972. Microbodies. Constituent organelles of animal cells. Lab. Invest. 27:184.

5. NOVIKOFF, A. B., P. M. NOVIKOFF, C. DAVIS, and N. QUINTANA. 1973. Studies on microperoxisomes V. Are microperoxisomes ubiquitous in mammalian cells? J. Histochem. Cytochem. 21:737.

6. TOLBERT, N. 1971. Microbodies—peroxisomes and glyoxysomes. Annu. Rev. Plant Physiol. 22:45.

7. DE DUVE, C., and P. BAUDHUIN. 1966. Peroxi-
somes (microbodies and related particles). Physiol. Rev. 46:323.

8. LEIGHTON, F., B. POOLE, P. LAZAROW, and C. de DUVE. 1969. The synthesis and turnover of rat liver peroxisomes. I. Fractionation of peroxisome proteins. J. Cell Biol. 41:521.

9. de DUVE, C. 1969. Evolution of the peroxisome. Ann. N. Y. Acad. Sci. 168:369.

10. NOVIKOFF, A. B., and S. GOLDFISCHER. 1968. Visualization of microbodies for light and electron microscopy. J. Histochem. Cytochem. 16:507.

11. FAHIMI, H. D. 1969. Cytochemical localization of peroxidatic activity of catalase in rat hepatic microbodies. J. Cell Biol. 43:275.

12. NOVIKOFF, A. B., and W. Y. SHIN. 1964. The endoplasmic reticulum in the Golgi zone and its relations to microbodies, Golgi apparatus, and autophagic vacuoles in rat liver cells. J. Microsc. (Paris). 3:187.

13. REDDY, J. K. 1973. Possible properties of microbodies (peroxisomes): Microbody proliferation and hypolipidemic drugs. J. Histochem. Cytochem. 21:567.

14. SVOBODA, D. J., and D. L. AZARNOFF. 1966. Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J. Cell Biol. 30:442.

15. SVOBODA, D., H. GRADY, and D. AZARNOFF. 1967. Microbodies in experimentally altered cells. J. Cell Biol. 35:127.

16. SVOBODA, D., D. AZARNOFF, and J. REDDY. 1969. Microbodies in experimentally altered cells. II. The relationship of microbody proliferation to endocrine glands. J. Cell Biol. 40:734.

17. REDDY, J., S. BUNYARATVEJ, and D. SVOBODA. 1969. Microbodies in experimentally altered cells. IV. Acatalasemic (Ca)$^+$ mice treated with CPIB. J. Cell Biol. 42:597.

18. REDDY, J., M. CHIGA, S. BUNYARATVEJ, and D. SVOBODA. 1970. Microbodies in experimentally altered cells. VII. CPIB-induced hepatic microbody proliferation in the absence of significant catalase synthesis. J. Cell Biol. 44:226-234.

19. OLIVER, M. 1963. Further observations on the effects of atronid and of ethyl-chlorophenoxyisobutyrate on serum lipid levels. J. Atheroscler. Res. 3:427.

20. BEST, M., and C. DUNCAN. 1964. Hypolipemia and hepatomegaly from ethyl chlorophenoxyisobutyrate (CPIB) in the rat. J. Lab. Clin. Med. 64:534.

21. REDDY, J., M. CHIGA, and D. SVOBODA. 1971. Stimulation of liver catalase synthesis in rats by ethyl-p-chlorophenoxyisobutyrate. Biochem. Biophys. Res. Commun. 43:318.

22. REDDY, J., D. SVOBODA, and D. AZARNOFF. 1973. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB. Biochem. Biophys. Res. Comm. 52:537-543.

23. HESS, R., and W. L. BENZCE. 1968. Hypolipidemic properties of a new retinol derivative (CIBA 13,437-SU). Experientia (Basel). 24:418.

24. BEST, M. M., and C. H. DUNCAN. 1970. Lipid effects of a phenolic ether (SU-13437) in the rat: Comparison with CPIB. Atherosclerosis. 12:185.

25. GANSCHOW, R. E., and R. T. SCHIMKE. 1969. Independent genetic control of the catalytic activity and the rate of degradation of catalase in mice. J. Biol. Chem. 244:4649.

26. LUCK, H. 1965. Catalase, Methods of Enzymatic Analysis. H. U. Bergmeyer, editor. Academic Press, Inc., New York. 805.

27. LOWRY, O. H., N. J. ROSEBOROUGH, A. L. FARL, and R. J. RANDALL. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265.

28. FEINSTEIN, R., J. BRAUN, and J. HOWARD. 1967. Acatalasemic and hypocatalasemic mouse mutants. II. Mutational variations in blood and solid tissue catalases. Arch. Biochem. Biophys. 120:165.

29. AEBI, H., H. SUTER, and R. N. FEINSTEIN. 1968. Activity and stability of catalase in blood and tissues of normal and acatalasemic mice. Biochem. Genet. 2:245.

30. SVOBODA, D. L. 1962. Micromethod for the determination of serum lipids. J. Lab. Clin. Med. 60:631.

31. FEINSTEIN, R., J. BRAUN, and J. HOWARD. 1967. Acatalasemic and hypocatalasemic mouse mutants. II. Mutational variations in blood and solid tissue catalases. Arch. Biochem. Biophys. 120:165.

32. KAMPSCHMIDT, R. F. 1965. Mechanism of liver catalase depression in tumor-bearing animals: a review. Cancer Res. 25:34.

33. HUBAN, Z., H. SWIFT, and A. SLESERS. 1966. Ultrastructural alterations of hepatic microbodies. Lab. Invest. 15:1884.

34. BECKETT, R. B., R. WEISS, R. E. STITZEL, and R. J. CENEDELLA. 1962. Studies on the hepatomegaly caused by the hypolipidemic drugs nafenopin and clofibrate. Toxicol. Appl. Pharmacol. 24:42.

35. REDDY ET AL. Nafenopin-Induced Microbody Proliferation 357
1969. Microbodies in experimentally altered cells. V. Histochemical and cytochemical studies on the livers of rats and acatalasemic mice treated with CPIB. Am. J. Pathol. 56:351.

38. Hochstein, P., and L. Ernster. 1963. ADPactivated lipid peroxidation coupled to the TPNH oxidase system of microsomes. Biochem. Biophys. Res. Commun. 12:388.

39. Barcelo, P., P. Puig-Muset, L. Sana Sola, J. Laporte, and F. G. Valdecasas. 1960. Premiéres études pharmacologiques sur lhepatocatalase et son emploi thérapeutique. Eur. Symp. Med. Enzymol. Proc. Mil. 342.

40. Caravaca, J., E. G. Dimond, S. C. Sommers, and R. Wenk. 1967. Prevention of induced atherosclerosis by peroxidase. Science (Wash. D. C.). 155:1284.

41. Cuadrado, R. R., and L. A. Bricker. 1973. An abnormality of hepatic lipogenesis in a mutant strain of acatalasemic mice. Biochim. Biophys. Acta 306:168.

42. Azarnoff, D., and D. Svoobra. 1969. Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect. Arch. Int. Pharmacodyn. Ther. 181:386.

43. Reddy, J. K. 1974. Hepatic microbody proliferation and catalase synthesis induced by methyl clofenapate, a hypolipidemic analogue of CPIB. Am. J. Pathol. In press.

44. Svoobra, D., and J. Reddy. 1972. Microbodies in experimentally altered cells. IX. The fate of microbodies. Am. J. Pathol. 67:541.